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Abstract
DNA amplification of exfoliated cells in stool repre-
sents an inexpensive and rapid test, but has only 50%
to 60% sensitivity. A new quantitative method, called
fluorescence long DNA, was developed and validated
in our laboratory on stool obtained from 86 patients
with primary colorectal cancer and from 62 healthy
individuals. It consists of the amplification of stool
DNA with fluorescence primers and the quantification
of the amplification using a standard curve. Results are
arbitrarily expressed in nanograms. The potential of the
new method compared to the conventional approach
was analyzed in a subgroup of 94 individuals (56
patients and 38 healthy volunteers). In the present
series, DNA amplification analysis showed a specific-
ity of 97% and a sensitivity of only 50%. Conversely,
fluorescence DNA evaluation, using the best cutoff of
25 ng, showed a sensitivity of about 76% and a spec-
ificity of 93%. Similar sensitivity was observed regard-
less of Dukes stage, tumor location, and size, thus
also permitting the detection of early-stage tumors.
The present study seems to indicate that quantitative
fluorescence DNA determination in stool successfully
identifies colorectal cancer patients with a sensitivity
comparable, if not superior, to that of multiple gene
analysis but at a lower cost and in a shorter time.
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Introduction
In recent years, a great deal of information has been
accumulated on the molecular alterations that take place
during the development of tumors, such as gene mu-
tations or genomic rearrangements, highlighting the possi-
bility of detecting tumor alterations in biologic fluids and,
consequently, indicating the use of these markers as a valid
noninvasive diagnostic approach.
A tumor that has been widely investigated with this
approach is colorectal cancer, which is one of the most
common forms of cancer worldwide, with a clinical outcome
varying considerably according to the type of lesion and
stage of disease at diagnosis [1–3]. An early diagnosis is
fundamental to reduce morbidity and mortality because a high
percentage of patients diagnosed in the early stages of disease
comprises long-term survivors [4]. Moreover, the possibility of
detecting premalignant lesions makes this tumor an ideal target
for screening programs. However, although several screening
methods are available, a high percentage of individuals does
not participate in colorectal cancer screening programs. There
are many reasons for this low compliance, such as a lack of
knowledge of the benefits of available screening methods,
especially colonoscopy, as well as the unpleasant and trouble-
some procedures [5].
Gene mutations in stool, especially K-ras [6–12] and, to a
lesser extent, p53 [13], APC gene [14,15], and microsatellite
instability [16], have been repeatedly investigated. Results
have shown the presence of these molecular alterations in
stool in only a fraction of patients, due to the relatively low
frequency of single marker alterations in colorectal cancer.
Multiple mutations have been analyzed in parallel on the same
stool sample, and this approach has led to improved test
sensitivity, but is expensive, time-consuming, and cannot eas-
ily be applied to screening programs [17–21].
The diagnostic potential of DNA amplification of exfoliated
cells in stool has recently been considered. Preliminary evi-
dence [19–21] has shown that the semiquantitative evaluation
of DNA amplification (long DNA, or L-DNA) of some DNA
fragments longer than 200 bp detects more than 50% of
colorectal cancers, with a very high specificity.
In the present study, we aimed to discuss the results ob-
tained from this inexpensive and rapid approach, both quanti-
tative and objective, to increase its accuracy and thus permit
a better discrimination between affected and nonaffected
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individuals. For this purpose, we assessed the diagnostic
potential of a new DNA amplification method (fluorescence
long DNA, or FL-DNA) on a series of patients and healthy
donors.
Patients and Methods
Case Series
Stool samples from 86 patients with primary colorectal
cancer were collected in the Gastroenterology Unit and
Department of Surgery I, Morgagni Hospital (Forlı`, Italy)
and in the Departments of Oncology and General Surgery,
Infermi Hospital (Rimini, Italy). Stool samples were collected
from 62 individuals who proved negative for cancer or benign
lesions after colonoscopy, and from laboratory personnel.
Stool samples were obtained at least 3 days after the
administration of laxative treatments in preparation for colo-
noscopy to allow for the recovery of normal bowel function-
ality. The fecal specimens were immediately frozen and
stored at 70jC for a maximum of 2 months.
Cancer diagnosis was histologically confirmed and path-
ological stage was defined according to Dukes classification:
8 tumors were classified as stage A, 30 as stage B, 37 as
stage C, and 9 as stage D. Moreover, 19 cancers were
located in ascending colon, 30 in descending colon, 2 in
transverse colon, and 35 in the rectal tract. Staging informa-
tion was not available for only two cases.
Of the 86 patients, 42 were male and 44 were female, and
median age was 72 years (range 36–90 years). Of the 62
controls, 29 were male and 33 were female, and median age
was 51 years (range 21–87 years).
DNA Purification
Approximately 4 g of stool was thawed at room temper-
ature. DNA was extracted after a 15-minute homogenization
with 16 ml of TE-9 buffer pH 9 (0.5 M Tris–HCl, 20 mM
EDTA, and 10 mM NaCl) by ULTRA-Turrax T25 (Janke
and Kunkel GmbH and Co. KG IKA-Labortechnik, Staufen,
Germany). After centrifugation at 5000g for 15 minutes, the
supernatant was transferred to a tube containing 5 ml of
7.5 M ammonium acetate (M-Medical, Florence, Italy) and
30 ml of 100% ethanol (Carlo Erba, Milan, Italy). DNA was
recovered by centrifugation at 5000g for 15 minutes at room
temperature. Stool samples were suspended in 1.6 ml of
ASL buffer and DNA was extracted using the QIAamp DNA
Stool Kit (QIAGEN, Hilden, Germany).
L-DNA Analysis
p53 exons 5 to 8 and fragments 1 to 4 of APC exon 15
were amplified in a final volume of 25 ml containing 2 ml of
DNA from stool, 0.4 mM of each primer, 200 mM deoxynu-
cleotide triphosphates, 1  reaction buffer with 3.5 mM
MgCl2, and 1 U of Taq polymerase (QIAGEN). The reaction
mixture was subjected to 38 polymerase chain reaction
(PCR) cycles: 60 seconds at 94jC, 60 seconds at 58jC,
and 60 seconds at 72jC. Primer sequences without fluores-
cence-labeled 5V ends have been described previously. Gel
electrophoresis was performed by running 5 ml of PCR
reaction in 2% agarose gel. In parallel, 5 ml of K-ras PCR
product and a control plasmid were used to verify the
presence of Taq inhibitors in fecal DNA samples. The relative
amplification intensities of p53 exons 5 to 8 and fragments
1 to 4 of APC were analyzed independently by two operators
and classified as high, medium, low, or not detectable. An
interobserver concordance was observed in all cases.
This semiquantitative L-DNA analysis was performed in
parallel with the quantitative FL-DNA approach in 94 individ-
uals (56 patients and 38 healthy volunteers) recruited during
the first period of the study.
FL-DNA Analysis
Amplifications of exons 5 to 8 of p53 and fragments 1 to 4
of APC exon 15 were carried out on 2 ml of DNA from stool
in a total volume of 25 ml containing 0.4 mM of each primer,
200 mM deoxynucleotide triphosphates, 1  reaction buffer
with 3.5 mM MgCl2, and 1 U of Taq polymerase (QIAGEN).
The reaction mixture was subjected to 32 cycles: 60 seconds
at 94jC and then 60 seconds at 60jC for p53 exons,
and 58jC for APC fragments, followed by incubation at
72jC for 60 seconds.
The p53 exons were amplified simultaneously in a single
reaction mixture and the four APC fragments were am-
plified in two different mixes (mix 1: fragments 1 and 2;
mix 2: fragments 3 and 4). For this purpose, primers used
for L-DNA analysis and those previously described [21]
were end-labeled with fluorochromes provided by Applied
Biosystems (Foster City, CA).
Electrophoresis was carried out using a 3100 Avant
Genetic Analyzer (Applied Biosystems) equipped with Gen-
eScan Analysis 3.7.
FL-DNA was performed by analyzing the fluorescence
intensity of each sample-specific PCR product. The quanti-
fication of each sample was calculated by reference to a
standard curve (1, 2, 5, 10, and 20 ng) of genomic DNA and
expressed as nanograms. To verify the presence or absence
of Taq inhibitors, amplification was performed on all samples
with a mix containing 2 ml of DNA extracted from stool and
25 ag of a plasmid with a control sequence. All determina-
tions were performed in duplicate and repeated in about
20% of samples in which the variation was >20%.
Statistical Analysis
FL-DNA concentrations were considered as a continuous
variable. The most accurate cutoff values to discriminate
between healthy donors and patients were calculated using
the receiver operating characteristic (ROC) curve. In the
ROC curves, sensitivity (true positive rate) was plotted
against 1specificity (false-positive rate) for all classification
points.
Sensitivity, specificity, and relative 95% confidence inter-
val (95% CI) were calculated for the most discriminant cutoff
values.
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Results
DNA amplification levels were evaluated by the semiquanti-
tative L-DNA method on stool samples from a series of 56
patients with primary colorectal cancer and 38 healthy indi-
viduals. DNA levels were expressed as the number of high
amplifications (i.e., as a discrete variable). A different distri-
bution was observed in affected and unaffected individuals
(Table 1). In particular, 79% (30 of 38) of healthy donors
showed no amplification, whereas at least one amplification
was observed in about 70% (39 of 56) of patients. The
analysis of the accuracy of this approach using different
cutoffs (Table 1) showed a very high specificity ranging from
79% to 100%. Conversely, sensitivity was very poor and did
not exceed 70% at any cutoff value.
Amplification levels of fecal DNA were analyzed by the
quantitative FL-DNA method in the overall series and
expressed as a continuous variable (Figure 1). Only one
stool sample from patients and three from healthy donors
were not evaluable due to the presence of Taq inhibitors.
Fluorescence signals ranged from 0 to 283 ng (median,
47 ng) in patient stool and from 0 to 87 ng (median, 4 ng) in
healthy donor stool. No differences in median values were
observed with respect to age of patients and the size, site,
and stage of tumor.
When the results from the two approaches were com-
pared, a direct relation was observed, but with a wide
variability of FL-DNA levels within the subgroups defined
according to the number of L-DNA high amplifications.
Moreover, fluorescence by FL-DNA method was detected
in 33 of 47 individuals who did not show any high amplifica-
tion by L-DNA assay. These results are clearly indicative of a
higher sensitivity of the fluorescence method than of the
conventional approach.
The ROC curve analysis of FL-DNA levels (Figure 2)
shows a good diagnostic accuracy of this approach. In
particular, very high specificity ranging from 83% to 95%
and high sensitivity ranging from 82% to 72% were observed
for the most discriminant cutoffs of 15, 20, 25, and 30 ng of
DNA (Table 2). When the cutoff of 25 ng, which provides the
best overall accuracy, was analyzed in relation to the differ-
ent tumor characteristics, sensitivity remained high in
patients with small tumors (70%) compared to large tumors
Table 1. Sensitivity and Specificity of L-DNA Analysis.
High
Amplifications
Healthy Donors Patients Sensitivity (%) Specificity (%)
At least 1 8/38 39/56 70 79
z2 1/38 28/56 50 97
z3 0/38 20/56 36 100
Figure 1. p53 analysis for FL-DNA quantification. (A) Amplification of scalar concentrations of genomic DNA using the same primers and conditions of stool sample
determination. (B) The area values under the electropherogram peaks are plotted in a calibration curve. (C) p53 electropherograms of six stool samples. The
amount of amplified DNA from individual samples is quantified on the basis of the calibration curve.
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(82%) and was similar for the different Dukes stage tumors
(Table 3). More importantly, a similar sensitivity was ob-
served in detecting tumors localized in ascending and
descending colon tracts.
Discussion
The possibility of performing population-based screening for
colorectal cancer as well as for all tumor types is dependent
on several factors such as complexity, time and cost, acces-
sibility, and acceptability of screening methods.
Although several screening methods are currently avail-
able and have proven effective in reducing colorectal cancer
mortality [22–27], a large-scale screening program compa-
rable to those used for breast or prostate cancer does not
exist. There are many reasons for this—the main one being
the uncertainty of the best strategy to adopt [fecal occult
blood test (FOBT), FOBT plus sigmoidoscopy, and so on].
Moreover, the real cost benefits of each method, considering
the large number of endoscopic or radiologic procedures
required for large-scale colorectal cancer screening, have
not been determined [28–31]. Another important reason is
that, for certain individuals, some of these techniques are not
easily accepted, further reducing the compliance of the
screening program itself [32].
A diagnostic approach that is less invasive, more accu-
rate, and optimized in terms of time and cost is undoubtedly
warranted. An important prospect is the analysis of molecu-
lar alterations detectable in human DNA extracted from stool.
Many authors have investigated this area by analyzing a
single molecular target or a combination of different molec-
ular targets [6–21]. An interesting target that has recently
been evaluated is the level of DNA amplification (L-DNA),
which appears to be related to the presence and number of
tumor cells in stool specimens. Only three studies to date
have evaluated this marker in combination with some spe-
cific gene alterations using a semiquantitative method of
analysis [19–21]. Their results show a good specificity and
a relatively low sensitivity of this approach—the latter pos-
sibly due to the lack of an objective and quantitative evalu-
ation, which compromises accurate discrimination between
affected and nonaffected individuals, or to the insufficient
sensitivity of the method.
In an attempt to improve the diagnostic accuracy of DNA
amplification in exfoliated cells from stool, we set up and
used an approach based on the evaluation of DNA amplifi-
cation by a fluorescence method (FL-DNA). The results
showed that this approach has a sensitivity comparable, if
not superior, to that of multiple gene analysis, but is less
expensive and less time-consuming. This sensitivity also
made it possible to detect small, low-grade, and early-stage
tumors. Moreover, unlike the fecal analysis of BAT26 insta-
bility or K-ras alterations, the determination of DNA amplifi-
cation is able to detect tumors in all colon sites [16,33].
These unique features make this molecular marker an
interesting tool for colorectal tumor diagnosis as it is char-
acterized by all the benefits of other molecular analyses,
such as noninvasiveness, simplicity, high compliance, rea-
sonable costs, and time-efficient procedures.
Furthermore, this method could be improved and simpli-
fied by using alternative quantification systems such as
chemoluminescence, spectrofluorimetry, real-time PCR,
and so on, with the aim of developing kits that can be more
easily utilized in all laboratories.
Figure 2. ROC curve of FL-DNA analysis for the overall series of stool
samples from patients and healthy donors.
Table 2. Sensitivity and Specificity of FL-DNA Analysis.
DNA Levels
Cutoff (ng)
Healthy Donors Patients Sensitivity (%) 95% CI Specificity (%) 95% CI
Positive Negative Positive Negative
15 10 49 70 15 82 (74–90) 83 (73–93)
20 7 52 70 15 82 (74–90) 88 (80–96)
25 4 55 65 20 76 (67–85) 93 (86–100)
30 3 56 61 24 72 (62–82) 95 (89–100)
Table 3. Sensitivity* as a Function of Different Characteristics in Colorectal
Cancer.
Category Number of Patients Positive Negative Sensitivity (%)
Size (cm)
0.1–4.0 40 28 12 70
z4.1 38 31 7 82
Dukes stage
A 8 7 1 88
B 29 25 4 86
C 37 25 12 68
D 9 8 1 89
Location
Ascending 18 13 5 72
Transverse 2 2 0 100
Descending 30 22 8 73
Rectum 35 28 7 80
*Cutoff value is 25 ng.
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Amore exhaustive study, including adenomas and benign
polyps, is needed to verify the real sensitivity and specificity
of this method. However, these original preliminary results
would seem to indicate the validity of this test and its
potential usefulness in screening programs or in monitoring
members of families at risk for colorectal cancer.
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